A multinational phase III study of PLX-PAD to improve recovery following surgery for femoral neck fracture

Trial Profile

A multinational phase III study of PLX-PAD to improve recovery following surgery for femoral neck fracture

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Muscle injury
  • Focus Registrational; Therapeutic Use
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 15 Nov 2016 According to a Pluristem Therapeutics media release, company has consulted with the European Medicines Agency (EMA) and are preparing for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) in early 2017 for this trial.
    • 05 Aug 2016 New trial record
    • 27 Jul 2016 According to a Pluristem Therapeutics media release, the company has designed the trial protocol with its Clinical Advisory Board (CAB), and planning to meet with FDA later in the year 2016 for the discussion. The company has already submitted the protocol of this study to the European Medicines Agency following consultation with the Adaptive Pathways Project Group.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top